Click here to sign in with or
Forget Password?
Learn more
share this!
23
Twit
Share
Email
April 26, 2024
This article has been reviewed according to Science X’s editorial process and policies. Editors have highlighted the following attributes while ensuring the content’s credibility:
fact-checked
proofread
by European Society of Clinical Microbiology and Infectious Diseases
Antimicrobial resistance (AMR) is continuing to increase globally, with rates of AMR in most pathogens increasing and threatening a future in which every day medical procedures may no longer be possible and infections thought long dealt with could kill regularly again. As such, new tools to battle AMR are vitally needed.
A new research review at this year’s ESCMID Global Congress (formerly ECCMID—Barcelona 27–30 April) shows how the latest CRISPR-Cas gene editing technology can be used to help modify and attack AMR bacteria. The presentation is by Dr. Rodrigo Ibarra-Chávez, Department of Biology, University of Copenhagen, Denmark.
CRISPR-Cas gene-editing technology is a groundbreaking method in molecular biology that allows for precise alterations to the genomes of living organisms. This revolutionary technique, which brought its inventors, Jennifer Doudna and Emmanuelle Charpentier, the Nobel Prize in Chemistry in 2020, enables scientists to accurately target and modify specific segments of an organism’s DNA (genetic code).
Functioning like molecular ‘scissors’ with the guidance of guide RNA (gRNA), CRISPR-Cas can cut the DNA at designated spots. This action facilitates either the deletion of unwanted genes or the introduction of new genetic material into an organism’s cells, paving the way for advanced therapies.
Dr. Ibarra-Chávez says, “Fighting fire with fire, we are using CRISPR-Cas systems (a bacterial immunity system) as an innovative strategy to induce bacterial cell death or interfere with antibiotic resistance expression—both hold promise as novel sequence-specific targeted ‘antimicrobials.'”
One line of their work involves creating guided systems against antimicrobial resistance genes that could treat infections and prevent dissemination of resistance genes.
Mobile genetic elements (MGEs) are parts of the bacterial genome that can move about to other host cells or also transfer to another species. These elements drive bacterial evolution via horizontal gene transfer. Dr. Ibarra-Chávez explains how repurposing mobile genetic elements (MGEs) and choosing the delivery mechanism involved in the antimicrobial strategy is important for reaching the target bacterium.
A phage is a virus that infects bacteria, and it is also considered MGE, as some can remain dormant in the host cell and transfer vertically. The MGEs his team is using are phage satellites, which are parasites of phages.
He says, “These ‘phage satellites’ hijack parts of the viral particles of phages to ensure their transfer to host cells. In contrast to phages, satellites can infect bacteria without destroying them, offering a step-change over existing methods involving phages and thus developing an arsenal of viral particles that are safe to use for applications such as detection and modification via gene delivery.
“Phage particles are very stable and easy to transport and apply in medical settings. It is our task to develop safe guidelines for their application and understand the resistance mechanisms that bacteria can develop.”
Bacteria can evolve mechanisms to evade the action of the CRISPR-Cas system and delivery vectors can be vulnerable to anti-MGE defenses. Thus Dr. Ibarra-Chávez’s team and others are developing the use of anti-CRISPRs and defense inhibitors in the delivery payloads to counter these defenses, to enable the CRISPR to arrive and attack the AMR genes in the cell.
Dr. Ibarra-Chávez also discusses how combination strategies employing CRISPR-Cas systems could promote antibiotic susceptibility in a target bacterial population. Phages have a particular selective pressure on AMR cells, which can improve the effect of some antibiotics. Similarly, using CRISPR-Cas in combination with phages and/or antibiotics, it is possible to suppress the mechanisms of resistance that infectious bacteria may develop by targeting such virulence/resistance genes, making these therapies safer.
He explains, “Bacteria are particularly good at adapting and becoming resistance. I believe we need to be cautious and try using combinatorial strategies to avoid the development of resistance, while monitoring and creating guidelines of new technologies.”
Dr. Ibarra-Chávez has primarily focused on tackling resistance in Staphylococcus aureus and Escherichia coli. Now, in collaboration with Prof. Martha Clokie and Prof. Thomas Sicheritz-Pontén, his team will treat group A Streptococci necrotizing soft tissue infection (flesh eating bacteria) using the combination approaches described above.
Provided by European Society of Clinical Microbiology and Infectious Diseases
Explore further
Facebook
Twitter
Email
Feedback to editors
23 hours ago
0
Apr 26, 2024
0
Apr 25, 2024
0
Apr 25, 2024
0
Apr 25, 2024
0
1 hour ago
2 hours ago
2 hours ago
19 hours ago
20 hours ago
20 hours ago
20 hours ago
20 hours ago
21 hours ago
21 hours ago
Apr 24, 2024
Apr 22, 2024
Apr 19, 2024
Apr 15, 2024
Apr 14, 2024
Apr 14, 2024
More from Biology and Medical
Oct 18, 2023
Apr 8, 2024
Aug 2, 2023
May 9, 2023
Apr 3, 2024
Feb 22, 2024
23 hours ago
22 hours ago
22 hours ago
22 hours ago
22 hours ago
Apr 26, 2024
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Phys.org in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
We keep our content available to everyone. Consider supporting Science X’s mission by getting a premium account.
Medical research advances and health news
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web